Adam Nelson completed his PhD at Dalhousie University in 2022, where his research focused on new combination therapies for pancreatic cancer using immunotherapy and oncolytic viruses. Following his PhD, he spent time as a Postdoctoral Fellow at Brigham & Women's Hospital and Harvard Medical School where he researched the role of macrophages in cancer treatment resistance. He is now back at Dalhousie university as a research associate.